NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

Trial Details

NCT ID
NCT06012695
Phase
PHASE1 / PHASE2
Sponsor
Novelwise Pharmaceutical Corporation
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • NBM-BMX Capsule
  • Temozolomide
  • Standard radiotherapy
Locations (sample)
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • Taichung, Taiwan|24.1469,120.6839
  • Taipei, Taiwan|25.05306,121.52639
  • Taoyuan City, Taiwan|24.99368,121.29696

Key Eligibility Criteria

  • Arm A (advanced solid tumors)
  • Having signed and dated the informed consent form.
  • Females or males \> 18 years old.
  • Histologically or cytologically confirmed advanced solid tumors refractory to standard of care therapy, or for which no standard of care therapy is…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →